The Pancreatic Cancer Action Network (PCAN) along with the Rising Tide Foundation for Clinical Cancer Research (RTF-CCR) and with the Gateway for Cancer Research (GCR) recently granted UT Southwestern $1 million to boost pancreatic cancer research over three years.
The funds, which were granted from the Clinical Continuation Research Grant, will be applied to the on-going research of Dr. David Boothman, PhD, professor and associate for translational research in pharmacology at UT Southwestern Medical Center.
This isn’t the first time Dr. Boothman’s research has received funding. In 2012, he received an Innovative Grant from the PCAN, who continues to recognize Dr. Boothman’s work by providing him with a new grant to be used after the end of his current Innovative Grant.
In his newly awarded project, entitled “Exploiting an NQO1 ‘Kiss of Death” for Pancreatic Cancer Therapy,” Dr. Boothman will collaborate with Dr. Shaalan Beg from UT Southwestern and with Dr. Daniel Laheru from John Hopkins University in a clinical trial to test abnormalities in pancreatic cells that could facilitate the elimination of tumors.
According to a recent press release,Teresa Hall Bartels, president of Gateway for Cancer Research, noted that the expected results from Dr. Boothman’s work may help to alleviate the weight of a cancer diagnostic “bringing us one step closer to Gateway’s vision of a world in which a cancer diagnosis is no longer feared.”
In addition, Eveline Mumenthaler, director of the RTF-CCR, highlighted the importance of the three-institution partnership to fund imperative research on one of the deadliest forms of cancer. “It is crucial that we support promising studies to further accelerate research that provides hopeful and immediate options for patients everywhere fighting this disease,” Mumenthaler added.
The partnership between these three institutions also allowed for the creation of The Transnational Continuation Research Grant, which will be awarded to Dr. David Ting, M.D., assistant physician and assistant professor in medicine at Harvard Medical School.
The $250,000 grant will support Dr. Ting’s project “Circulating Tumor Cells to Assess Pancreatic Cancer Disease Status,” a research project started in 2009 when he received a Fellowship Award from the PCAN.
PCAN has previously awarded sixteen grants in a total of $5.1 million this year to fund scientists currently researching pancreatic cancer, the fourth cause of cancer-related deaths and the probable second cause by 2020. Pancreatic cancer also has the lowest five-year survival rate of 6% at the present.